Worg Pharmaceuticals, a Hangzhou-based developer of allergic drugs, has received the green light from the US Food and Drug Administration (FDA) to proceed with a Phase II clinical study for its drug candidate WP1302 in the treatment of Graves’ disease.
Graves’ disease, a prevalent autoimmune condition, impacts an estimated 10 million individuals in Europe and America. Characterized by the immune system’s erroneous assault on the thyroid gland, the disease leads to an overproduction of thyroid hormones, resulting in hyperthyroidism symptoms such as weight loss and exophthalmos. WP1302, pioneering as the first targeted immunotherapy for Graves’ disease, has demonstrated significant therapeutic effects for the majority of patients in Phase I clinical trials, along with a favorable safety profile.- Flcube.com
